Non-Small-Cell Lung Cancer – Landscape & Forecast – Disease Landscape & Forecast (G7)
The multibillion-dollar NSCLC therapy market is highly dynamic, with a plethora of approved therapies but still a high unmet need. Immune checkpoint inhibitors such as Keytruda (Merck & Co.), which gained label expansions in the resectable early-stage space in 2023, have broad applicability in many stages and settings of NSCLC and dominate the field. Biomarker-targeted therapeutics increasingly drive segmentation of the market, exemplified by 2023 entrants Braftovi plus Mektovi and Augtyro. Continued drug development in the biomarker and immune checkpoint inhibitor classes, plus expected new market entrants, will further drive competition in the commercially lucrative NSCLC market.
Questions answered
- How will the recent and expected new market entrants shape the treatment landscapes in the various settings and stages (I-IV) of NSCLC?
- Which therapies will dominate the commercially lucrative first-line metastatic NSCLC setting?
- What are the most promising late-phase pipeline products, and what will be their likely uptake and patient share in NSCLC?
- What are the key drivers and constraints of the NSCLC therapy market, and how will the market evolve over the forecast period?
Product description
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Key features
Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.
Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.
Table of contents
- Non-Small-Cell Lung Cancer - Landscape & Forecast - Disease Landscape & Forecast (G7)
- Executive Summary
- Key Updates
- Market Forecast
- Disease Context
- Epidemiology
- Current Treatment
- Key takeaways
- Treatment for NSCLC
- Early-stage (stage I-III) NSCLC
- Metastatic NSCLC
- Treatment decision tree for early-stage (stage I-III) NSCLC
- Treatment decision tree for metastatic (stage IV) NSCLC with EGFR, ALK, BRAF V600E, ROS1, RET, or MET exon 14 skipping alterations
- Treatment decision tree for metastatic (stage IV) NSCLC with KRAS G12C, HER2, or NRG1 alterations, MET overexpression, or without actionable mutations
- Key current therapies
- Key takeaways
- Emerging Therapies
- Key takeaways
- Key emerging therapies
- Immune checkpoint inhibitors
- Immune system stimulators
- EGFR inhibitors
- ALK inhibitors
- ROS1 inhibitors
- MET-targeting agents
- KRAS inhibitors
- RAS inhibitors
- HER2- and HER3-targeting agents
- TROP2-targeting ADCs
- Integrin beta-6-targeting ADCs
- ATR inhibitors
- Adoptive cell therapies
- Therapeutic vaccines
- PARP inhibitors
- Cytokine-targeting agents
- Unmet need
- Key takeaways
- Drug Pipeline
- Appendix
- Executive Summary
